In the phase III PALOMA-2 trial, although the expression levels of genes in the Cyclin D-CDK4/6-RB pathway did not correlate with a benefit from palbociclib plus letrozole, 59 breast cancer patients without P16 expression exhibited a benefit [39, 40]. This evidence concerns the gene RB1 and breast cancer.